Baldness Increases PCa Risk
Androgenic alopecia, also known as male pattern baldness, is significantly associated with an elevated risk for prostate cancer (PCa).
AUA 2012 Prostate Cancer
New Assay Identifies Men Who May Be at Lower Risk for PCa Recurrence After Surgery
A recently approved diagnostic assay may improve clinicians’ ability to predict a prostate cancer patient’s risk of clinical recurrence after radical prostatectomy (RP), a company announced at the American Urological Association 2012 annual meeting.
Oral Drug Prolongs Survival in Men with Late-Stage PCa
Enzalutamide, an investigational oral medication formerly known as MDV3100, prolongs survival by nearly five months in men with late-stage prostate cancer previously treated with docetaxel, according to data presented at the American Urological Association 2012 annual meeting.
Intermittent ADT May Offer Survival Edge in Advanced Prostate Cancer
Intermittent androgen deprivation (IAD) therapy is associated with improved all-cause and prostate cancer (PCa)-specific mortality among elderly patients with advanced PCa, according to data presented at the American Urological Association 2012 annual meeting.
Durable Oncologic Outcomes Reported for RARP
Robotic-assisted radical prostatectomy (RARP) is associated with long-term biochemical relapse-free survival, according to a study presented at the American Urological Association 2012 annual meeting.
UI Incidence Low After Image-Guided Radiation Therapy
Prostate cancer (PCa) patients undergoing image-guided radiation therapy (IGRT) experience a low incidence of treatment-related urinary incontinence (UI), researchers reported at the American Urological Association 2012 annual meeting.
Urologists Condemn Task Force’s Anti-PSA Testing Stance
The U.S. Preventive Services Task Force (USPSTF) on May 21 released its final recommendations on PSA-based screening for prostate cancer (PCa), which advises against the practice and gives it a grade D rating, meaning the task force believes there is “moderate or high certainty that the service has no net benefit or that the harms outweigh the benefit.”
Post-RP Survival Unaffected by Early Biochemical Recurrence
Early biochemical recurrence after radical prostatectomy (RP) has no effect on survival among patients with low-risk prostate cancer (PCa), according to a study presented at the American Urological Association 2012 annual meeting.
HIFU Salvage Following EBRT Offers Good PCa Control
High-intensity focused ultrasound (HIFU) provides shows promise as a salvage treatment option men with recurrent prostate cancer (PCa) following external beam radiotherapy (EBRT), data presented at the American Urological Association annual meeting suggest.
PCa-Specific Survival Can Be Good Even with Positive Nodes
Prostate cancer (PCa) patients with lymph node positive disease found at radical prostatectomy (RP) can experience durable cancer-specific and metastases-free survival, researchers reported at the American Urological Association 2012 annual meeting.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...